The Access Industries and Eli Lilly-backed genetic drug developer floated at the top of its range having increased the number of shares in the offering by 60%.
Passage Bio, a US-based genetic medicine developer backed by conglomerate Access Industries and pharmaceutical firm Eli Lilly, raised $216m in its initial public offering today.
The company is issuing 12 million shares on the Nasdaq Global Select Market priced at the top of the IPO’s $16 to $18 range, having first increased the number of shares from 7.4 million to 10 million and then adding a further 2 million.
Founded in 2017, Passage Bio is developing genetic therapies for rare,…
